ICU dan Non-ICU MRSA: Kejadian dan Faktor Risiko di Rumah Sakit Tersier
Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that is resistant to penicillin-class antibiotics and poses a serious threat to healthcare facilities. Its global prevalence reached 30% in 2020, while in Indonesia it ranges from 0.3% to 52%, with the highest rate reported in Jakarta.
Objective: To compare the incidence and risk factors of MRSA among patients in the Intensive Care Unit (ICU) and general wards (non-ICU) at RSUP Haji Adam Malik Medan, during 2022–202.
Methods: A cross-sectional study was performed on 569 patients in ICU and non-ICU wards with culture examinations performed from January 2022 to December 2023. Bivariate analysis was conducted for nine independent variables, followed by multivariate logistic regression for variables with p-values < 0.25.
Results: From 18,121 culture examinations, 569 isolates of Staphylococcus aureus were identified. MRSA incidence was higher in non-ICU wards (246 of 441 isolates; 55.7%) than in the ICU (63 of 128 isolates; 49.2%). Statistically significant risk factors differed between the two groups: in ICU patients, only diabetes mellitus (OR 2.50; p = 0.017) was significant; while in non-ICU patients, chronic kidney disease (OR 0.644; p = 0.037) and a history of prior antibiotic use (OR 3.037; p = 0.011) were significant factors. Additionally, 4.21% of all isolates were confirmed as VRSA.
Conclusion: MRSA incidence was higher among patients in non-ICU wards. The main risk factors differed between units: diabetes mellitus was prominent among ICU patients, whereas chronic kidney disease and previous antibiotic use played a role among non-ICU patients. These differences highlight the need for infection prevention and control strategies tailored to the specific risk profiles of each care unit.
References
2. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616–87.
3. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: World Health Organization; 2014.
4. Goudarzi M, Fazeli M, Azad M, Sadredin A, Nazeri S, Khosravi AD. Molecular characterization of methicillin-resistant Staphylococcus aureus isolated from hospitalized patients in ICU in Iran. J Infect Dev Ctries. 2020;14(11):1273–9.
5. Retnoningrum DS, Pudjiastuti P, Nurwidya F. Prevalence and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) in Indonesia: a systematic review. Infect Dis Rep. 2020;12(Suppl 1):8702.
6. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.
7. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99–139.
8. Tacconelli E, Carrara E, Savoldi A, al. et. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.
9. Said KB, Alshammari K, Ahmed RME, Alshammari F, Jadani AH, Rakha I, et al. MRSA Profiles Reveal Age- and Gender-Specificity in a Tertiary Care Hospital: High Burden in ICU Elderly and Emerging Community Patterns in Youth. Microorganisms. 2025;13(5):1–17.
10. Syam B, Ismail M, Syam Y. Analysis of Factors Related to The Incidence of Methicillin-Resistant Staphylococcus Aureus ( MRSA ) At Makassar City Hospital. 2025;8(2):124–33.
11. Azzam A, Khaled H, Fayed HM, Mansour Y, Eldalil M, Elshennawy E, et al. Prevalence, antibiogram, and risk factors of methicillin-resistant Staphylococcus aureus (MRSA) asymptomatic carriage in Africa: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1).
12. V. A, R. P, M. B. Prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) infections among patients admitted in critical care units in a tertiary care hospital. Int J Res Med Sci. 2017;5(6):2362.
13. Yates C, May K, Hale T, Allard B, Rowlings N, Freeman A, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907–9.
14. Kim YS, Kim J, Cheon S, Sohn KM. Higher risk for all-cause mortality of staphylococcus aureus bacteremia in patients with non-dialysis dependent chronic kidney disease. Infect Chemother. 2020;52(1):82–92.
15. Ahmad F, Sennang N, Rusli B. Vancomycin Resistant Staphylococcus Aureus in Dr. Wahidin Sudirohusodo Hospital Makassar. Indones J Clin Pathol Med Lab. 2019;25(2):194–8.
16. Blechman SE, Wright ES. Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLoS Pathog [Internet]. 2024;20(8):1–27. Tersedia pada: http://dx.doi.org/10.1371/journal.ppat.1012422
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.